Disease · MONDO_0017590

carcinoma of the ampulla of vater

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. carcinoma of the ampulla of vater. Diseases, record MONDO_0017590. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017590

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: carcinoma of the ampulla of vater; Open Targets
Open Targets ID: MONDO_0017590; Open Targets
Other names: Ampulloma, ampulla of Vater cancer, ampulla of Vater carcinoma, ampullary cancer, ampullary carcinoma, carcinoma of ampulla of vater, carcinoma of hepatopancreatic ampulla, hepatopancreatic ampulla carcinoma; Open Targets
Disease Ontology: DOID:4932; Disease Ontology
NCI Thesaurus: C3908; NCI Thesaurus
Orphanet: ORPHA:300557; Orphanet
Highest stage of its drugs: Phase 3, for 6 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FOSGEMCITABINE PALABENAMIDE	CHEMBL3126004	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RETIFANLIMAB	CHEMBL4298037	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets33

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5426	Drugs and targets
POLE2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5427	Drugs and targets
POLE3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/54107	Drugs and targets

1 to 10 of 33

See all 33 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04163900	Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer	Phase 3	773	2023-05-24	Biliary Tract Cancer	CISPLATIN, FOSGEMCITABINE PALABENAMIDE, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT04116073	INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer	Phase 2	25	2025-07-29	Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic	RETIFANLIMAB	Its record names the disease	ClinicalTrials.gov
NCT01926236	Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers	Phase 3	162		Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer	FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00552149	Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin	Phase 2	150		Advanced Biliary Cancer	CETUXIMAB, GEMCITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT04492033	A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients	Phase 1/2	41		P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer	IRINOTECAN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00987766	Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer	Phase 1	28		Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer, Periampullary Adenocarcinoma, Small Intestine Cancer	ERLOTINIB HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: deaths from any cause	188 of 388	135 of 385	773	NCT04163900	Trial comparisons
A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: serious adverse events	175 of 383	126 of 378	761	NCT04163900	Trial comparisons
A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: Objective Response Rate (ORR)	53 of 284	34 of 275	559	NCT04163900	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39978598	DERIVED	1	PubMed
33798493	DERIVED	1	PubMed
32374623	DERIVED	1	PubMed
24852116	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017590

GET https://conductscience.org/api/diseases/v1/MONDO_0017590/targets?page=2

API reference For AI assistants